Edwards Lifesciences Co. (NYSE:EW) VP Sells $27,792.00 in Stock

Edwards Lifesciences Co. (NYSE:EW) VP Daniel J. Lippis sold 400 shares of Edwards Lifesciences stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.48, for a total value of $27,792.00. Following the sale, the vice president now directly owns 22,588 shares of the company’s stock, valued at approximately $1,569,414.24. The trade was a 1.74 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Edwards Lifesciences Stock Performance

EW stock traded down $1.85 on Monday, reaching $68.49. 4,773,170 shares of the company were exchanged, compared to its average volume of 4,508,592. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The stock’s fifty day moving average price is $72.14 and its 200 day moving average price is $70.37. The firm has a market capitalization of $40.26 billion, a PE ratio of 9.83, a PEG ratio of 4.82 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, research analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on EW. Morgan Stanley lifted their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 12th. Canaccord Genuity Group upped their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday, February 13th. Truist Financial reiterated a “hold” rating and issued a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and upped their price objective for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Finally, The Goldman Sachs Group upped their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $79.95.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Crowley Wealth Management Inc. acquired a new position in shares of Edwards Lifesciences in the fourth quarter valued at $26,000. Vega Investment Solutions bought a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $27,000. Millstone Evans Group LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $29,000. FSA Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the 3rd quarter worth approximately $30,000. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $30,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.